Skip to main content

CORRECTION article

Front. Immunol., 16 July 2018
Sec. Cancer Immunity and Immunotherapy
Volume 9 - 2018 | https://doi.org/10.3389/fimmu.2018.01641

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

This article is a correction to:

  1. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

    1. Read original article
\r\nM. Fevzi Ozkaynak*M. Fevzi Ozkaynak1*Andrew L. GilmanAndrew L. Gilman2Wendy B. LondonWendy B. London3Arlene NaranjoArlene Naranjo4Mitchell B. DiccianniMitchell B. Diccianni5Sheena C. TenneySheena C. Tenney4Malcolm SmithMalcolm Smith6Karen S. MesserKaren S. Messer5Robert SeegerRobert Seeger7C. Patrick ReynoldsC. Patrick Reynolds8L. Mary SmithL. Mary Smith9Barry L. ShulkinBarry L. Shulkin10Marguerite ParisiMarguerite Parisi11John M. MarisJohn M. Maris12Julie R. ParkJulie R. Park11Paul M. SondelPaul M. Sondel13Alice L. Yu,*Alice L. Yu5,14*for the Children&#x;s Oncology Group (COG) for the Children’s Oncology Group (COG)
  • 1New York Medical College, Valhalla, NY, United States
  • 2Levine Children’s Hospital, Charlotte, NC, United States
  • 3Dana Farber Cancer Institute and Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States
  • 4Children’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL, United States
  • 5Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States
  • 6National Cancer Institute, Bethesda, MD, United States
  • 7Children’s Hospital Los Angeles, University Southern California, Los Angeles, Los Angeles, CA, United States
  • 8Texas Tech University Health Sciences Center, Lubbock, TX, United States
  • 9United Therapeutics, Silver Spring, MD, United States
  • 10St. Jude’s Children’s Research Hospital, Memphis, TN, United States
  • 11Seattle Children’s Hospital, University of Washington School of Medicine, Seattle, WA, United States
  • 12Children’s Hospital of Philadelphia, Philadelphia, PA, United States
  • 13University of Wisconsin Carbone Cancer Center, Madison, WI, United States
  • 14Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan

A corrigendum on

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, et al. Front Immunol (2018) 9:1355. doi: 10.3389/fimmu.2018.01355

In the original article, we neglected to include the funder NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick’s Foundation.

The revised “Funding” should read:

This work was supported by ARRA grant from the National Institutes of Health, by grant from the Department of Defense (AY) # W81XWH-12-1-0427, by grant from the NIH (AY) #5R01CA164132, the Lou Bridgeman Memorial Fund, the Alex’s Lemonade Stand Foundation (AY), NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick’s Foundation and COG SDC grant U10CA180899.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: neuroblastoma, immunotherapy, anti-GD2 chimeric antibody, cytokines, safety, cytokine biomarkers

Citation: Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM and Yu AL (2018) Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931. Front. Immunol. 9:1641. doi: 10.3389/fimmu.2018.01641

Received: 02 July 2018; Accepted: 03 July 2018;
Published: 16 July 2018

Edited and Reviewed by: Frontiers in Immunology Editorial Office, Frontiers Media SA, Switzerland

Copyright: © 2018 Ozkaynak, Gilman, London, Naranjo, Diccianni, Tenney, Smith, Messer, Seeger, Reynolds, Smith, Shulkin, Parisi, Maris, Park, Sondel and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: M. Fevzi Ozkaynak, bWVobWV0X296a2F5bmFrJiN4MDAwNDA7bnltYy5lZHU=;
Alice L. Yu, YTF5dSYjeDAwMDQwO3Vjc2QuZWR1

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.